MX2019010913A - Analogos de deutetrabenazina, su preparacion y uso. - Google Patents

Analogos de deutetrabenazina, su preparacion y uso.

Info

Publication number
MX2019010913A
MX2019010913A MX2019010913A MX2019010913A MX2019010913A MX 2019010913 A MX2019010913 A MX 2019010913A MX 2019010913 A MX2019010913 A MX 2019010913A MX 2019010913 A MX2019010913 A MX 2019010913A MX 2019010913 A MX2019010913 A MX 2019010913A
Authority
MX
Mexico
Prior art keywords
deutetrabenazine
analogs
preparation
compositions
same
Prior art date
Application number
MX2019010913A
Other languages
English (en)
Spanish (es)
Inventor
Kerr Jim
Zhang Chengzi
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of MX2019010913A publication Critical patent/MX2019010913A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Pens And Brushes (AREA)
  • Machine Translation (AREA)
MX2019010913A 2017-03-15 2018-03-15 Analogos de deutetrabenazina, su preparacion y uso. MX2019010913A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762471484P 2017-03-15 2017-03-15
PCT/US2018/022562 WO2018170214A1 (en) 2017-03-15 2018-03-15 Analogs of deutetrabenazine, their preparation and use

Publications (1)

Publication Number Publication Date
MX2019010913A true MX2019010913A (es) 2020-01-20

Family

ID=61873991

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010913A MX2019010913A (es) 2017-03-15 2018-03-15 Analogos de deutetrabenazina, su preparacion y uso.

Country Status (20)

Country Link
US (4) US11813232B2 (https=)
EP (1) EP3596077A1 (https=)
JP (3) JP7608050B2 (https=)
KR (2) KR20200003791A (https=)
CN (1) CN110709398A (https=)
AR (1) AR111182A1 (https=)
AU (2) AU2018236336B2 (https=)
BR (1) BR112019018966A2 (https=)
CA (1) CA3056612A1 (https=)
CL (1) CL2019002629A1 (https=)
CO (1) CO2019011271A2 (https=)
EA (1) EA201992168A1 (https=)
IL (1) IL269132A (https=)
MX (1) MX2019010913A (https=)
PE (1) PE20191819A1 (https=)
SG (1) SG11201908477QA (https=)
TW (1) TWI772382B (https=)
UA (1) UA127052C2 (https=)
WO (1) WO2018170214A1 (https=)
ZA (1) ZA201906326B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20191819A1 (es) 2017-03-15 2019-12-27 Auspex Pharmaceuticals Inc Analogos de deutetrabenazina, su preparacion y uso
KR20210114946A (ko) 2018-12-13 2021-09-24 오스펙스 파마슈티칼스, 인코포레이티드 뇌성마비에서의 운동이상증의 치료를 위한 듀테트라베나진
WO2020165807A1 (en) * 2019-02-14 2020-08-20 Dr. Reddy's Laboratories Limited Solid forms of deutetrabenazine and process for the preparation thereof
US11311488B2 (en) 2020-06-10 2022-04-26 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
US12599598B2 (en) 2020-06-10 2026-04-14 Auspex Pharmaceuticals Llc Osmotic dosage forms comprising deutetrabenazine and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081929B1 (en) 2006-11-08 2013-01-09 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
CA2972242A1 (en) * 2008-09-18 2010-04-22 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP3351247A1 (en) * 2010-06-01 2018-07-25 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
WO2012081031A1 (en) * 2010-12-15 2012-06-21 Enaltec Labs Pvt. Ltd. Process for preparing tetrabenazine
US9550780B2 (en) * 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
EP4345100A3 (en) * 2012-09-18 2024-04-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2015084622A1 (en) * 2013-12-03 2015-06-11 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
AU2016229949B2 (en) 2015-03-06 2021-04-08 Auspex Pharmaceuticals Llc Methods for the treatment of abnormal involuntary movement disorders
PE20191819A1 (es) 2017-03-15 2019-12-27 Auspex Pharmaceuticals Inc Analogos de deutetrabenazina, su preparacion y uso

Also Published As

Publication number Publication date
KR20200003791A (ko) 2020-01-10
JP2024050724A (ja) 2024-04-10
JP7608050B2 (ja) 2025-01-06
US11179386B2 (en) 2021-11-23
CN110709398A (zh) 2020-01-17
TW201840317A (zh) 2018-11-16
IL269132A (en) 2019-11-28
CA3056612A1 (en) 2018-09-20
JP2023010754A (ja) 2023-01-20
AU2018236336B2 (en) 2022-02-24
JP7631572B2 (ja) 2025-02-18
SG11201908477QA (en) 2019-10-30
US20220088006A1 (en) 2022-03-24
BR112019018966A2 (pt) 2020-04-22
US20220040170A1 (en) 2022-02-10
WO2018170214A1 (en) 2018-09-20
AU2022203369B2 (en) 2024-04-04
US12502385B2 (en) 2025-12-23
AU2022203369A1 (en) 2022-06-09
US20180263972A1 (en) 2018-09-20
NZ757789A (en) 2024-08-30
TWI772382B (zh) 2022-08-01
EA201992168A1 (ru) 2020-03-16
CL2019002629A1 (es) 2020-01-24
KR20230003308A (ko) 2023-01-05
AU2018236336A1 (en) 2019-10-24
JP2020510073A (ja) 2020-04-02
US20200016148A1 (en) 2020-01-16
UA127052C2 (uk) 2023-03-29
EP3596077A1 (en) 2020-01-22
US11813232B2 (en) 2023-11-14
ZA201906326B (en) 2022-12-21
PE20191819A1 (es) 2019-12-27
CO2019011271A2 (es) 2020-02-28
AR111182A1 (es) 2019-06-12

Similar Documents

Publication Publication Date Title
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
TWD180147S (zh) 淨水器
MX385845B (es) Usos y composiciones de la flagelina
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
MX2017006217A (es) Polinucleotidos moduladores.
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
PH12017500836A1 (en) Transdermal formulations
JO3794B1 (ar) المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2017017124A (es) 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
MX2019010913A (es) Analogos de deutetrabenazina, su preparacion y uso.
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
MX386700B (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
JOP20200126B1 (ar) طرق استخدام وتركيبات تحتوي على دولاجلوتيد
MX2017014971A (es) Composiciones de sal mejoradas y metodo de preparacion de las mismas.
MX2015016603A (es) Composiciones de corticosteroides.
MX383313B (es) Compuestos de quinolinilciclohexilpropanamida sustituidos y metodos mejorados para su preparacion
MX2016015017A (es) Composiciones dentifricas con estabilidad mejorada del fluoruro.
ECSP18050673A (es) Formulaciones de giberelina en solución concentrada
MX383947B (es) Composiciones de colágeno 7 y métodos para usar las mismas.
EA201890209A1 (ru) Композиция, содержащая танины
MX368972B (es) Composiciones de glicoproteínas sialiladas y usos de estas.
NZ721832A (en) Solid forms of tenofovir
MX2015015850A (es) Composiciones de sabor y fragancia que contienen tiopiran-carbaldehido.